FDA Warns Buying Young Blood as an Anti-Aging Treatment is Harmful

On Tuesday, the US Food and Drug Administration warned against using young blood transfusion to prevent aging and other health conditions. The treatment contains plasma, the liquid part of the blood that helps clot blood. Scott Gottlieb, FDA commissioner and Peter Marks, director of the Center for Biologics Evaluation and Research, cautioned in a notice against blood infusions. They said, claims that these transfusions can assist in treating conditions such as dementia, Alzheimer’s disease, heart disorders do not have any clinical proof of results. Both men have significant public health concerns about the advertisement and the use of plasma for treatment. Many risks are linked with the use of any plasma product.

One questionable company, Ambrosia, is offering blood to consumers. It costs $8,000 for 1 liter of blood and $12,000 for two liters. Jesse Karmazin is the founder of the company, and a Stanford Medical School Graduate. He says the treatment can reverse the aging process and cure-all diseases. Whereas, the FDA statement noted that it does not have verified scenarios for young blood infusion. Scott says simply infusing plasma is not a kind intervention and should not be followed as a cavalier fashion. New procedures are necessary to undergo various researches to know whether they are safe or not. The FDA studies and reviews the information before permitting a treatment to arrive in the market.

The leading company in the field, Ambrosia Medical, started its own study and tests in 2017. The new FDA warning targeted the startup company, which seems to have breached rules of FDA. On Tuesday, the company stopped patient treatments in compliance with the FDA’s announcement. Ambrosia also displayed a message on its website. FDA said it would take strict action against the companies that misuse patients trust. Scott said the agency started with a warning to customers because the FDA has immediate concerns. The FDA said it would observe the matter and take appropriate actions with state and local health governments and blood organizations.

Leave a Reply

Your email address will not be published. Required fields are marked *